| Drug Name: | Auranofin (34031-32-8) |
|---|---|
| PubChem ID: | 24199313 |
| SMILES: | CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+] |
| InchiKey: | AUJRCFUBUPVWSZ-UHFFFAOYSA-M |
| Therapeutic Category: | Antirheumatic Agents |
| Molecular Weight (dalton) | : | 678.491 |
| LogP | : | 2.1419 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 10 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 114.43 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Naproxen (22204-53-1) | Pneumonitis | Antagonistic | Not Established | Gold-naproxen pneumonitis A toxic drug interaction |
| Acetylsalicylic acid (50-78-2) | Liver Damage | Antagonistic | Not Established | Fenoprofen, aspirin, and gold induction in rheumatoid arthritis |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Persistent Loose Stools | Metallothionein (P04731) | Developed persistent loose stools. [ ADR Type 2 ] | Auranofin treatment of rats: adaptation to intestinal adverse effects and observations on the cytosolic distribution of gold in the intestines, liver and kidneys |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category